This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Drug Drug Interactions of Aspirin and P2Y12-inhibitors

This study has been completed.
Information provided by (Responsible Party):
Eva-Luise Hobl, Medical University of Vienna Identifier:
First received: June 7, 2011
Last updated: March 23, 2017
Last verified: March 2017
Study Objective: To investigate potential drug-drug interactions (pharmacokinetics and pharmacodynamics) of morphine and antiplatelet drugs (aspirin, clopidogrel, prasugrel, ticagrelor)

Condition Intervention Phase
Drug Interaction Potentiation Myocardial Infarction Drug: Morphine Drug: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Drug Drug Interactions of Antiplatelet Drugs and Morphine

Resource links provided by NLM:

Further study details as provided by Eva-Luise Hobl, Medical University of Vienna:

Primary Outcome Measures:
  • Platelet function [ Time Frame: 14 days ]

Secondary Outcome Measures:
  • Tmax [ Time Frame: 14 days ]
  • Cmax [ Time Frame: 14 days ]

Enrollment: 95
Study Start Date: May 2011
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Morphine
Vendal 5 mg i.v. bolus injection
Drug: Morphine
i.v. bolus injection
Other Name: Vendal
Placebo Comparator: Placebo
Sodium chloride 0.9% i.v. bolus injection
Drug: Placebo
i.v. bolus injection
Other Name: Sodium chloride 0,9%

Detailed Description:
Rationale: Opiates reduce the intestinal resorption of orally administered drugs such as paracetamol. Because morphine is often injected to relieve pain in patients with myocardial infarction, it is of particular interest if morphine may decrease the rate of absorption of antiplatelet drugs. Results of this study will provide essential information for the use of morphine and antiplatelet drugs in clinical practice, in particular in myocardial infarction.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy volunteers ≥ 18 years of age
  • No intake of NSARs and P2Y12-inhibitors within 14 days before study entry
  • Written informed consent

Exclusion Criteria:

  • Known coagulation disorders
  • Relevant impairment of hepatic function (elevated transaminases, ≥ 2 fold)
  • Relevant impairment of renal function
  • Infectious diseases (HIV, hepatitis B and C)
  • Gestation and lactation
  • Clinically relevant abnormal laboratory values
  • Use of medication during 2 weeks before the start of the study, which may affect the validity of the study
  • General contraindications for aspirin (resp. clopidogrel, prasugrel, ticagrelor) and morphine
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01369186

Medical University of Vienna, Department of Clinical Pharmacology
Vienna, Austria, 1090
Sponsors and Collaborators
Medical University of Vienna
Principal Investigator: Bernd Jilma, Prof. Dr. Medical University of Vienna
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Eva-Luise Hobl, Dr., Medical University of Vienna Identifier: NCT01369186     History of Changes
Other Study ID Numbers: 2010-023761-22
Study First Received: June 7, 2011
Last Updated: March 23, 2017

Additional relevant MeSH terms:
Myocardial Infarction
Pathologic Processes
Myocardial Ischemia
Heart Diseases
Cardiovascular Diseases
Vascular Diseases
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents processed this record on September 19, 2017